Current Status and Alturas’ Ongoing Response to COVID-19
Updated 13May2020

Ongoing Research

Since inception in 2000, Alturas Analytics has been collaborating with innovators and leading pharmaceutical scientists to assist in developing novel technologies designed for the specific needs of the bioanalytical chemist.

Projects currently in development at Alturas include the application of immuno-capture techniques, and automation and miniaturization in combination with the latest MFLC-MS/MS instrumentation for the quantification of oligonucleotides, biomarkers and anti-drug antibodies. Advances in technology allow for transition of biomolecule analysis from traditional ligand-binding assays (LBAs) to MS platforms. The time to bring an assay into production can be greatly decreased and the reliability of the data generated improves when compared to LBAs. 

Alturas is a known pioneer in applying PicofuzeTM technology interfaced with MicroFlow Liquid Chromatography and Tandem Mass Spectrometry (MFLC-MS/MS) and for developing microsample analysis procedures for both small and large molecules.

Implementation of novel technologies to routine workflows in the regulated bioanalytical laboratory is the standard working model at Alturas Analytics. This model has been proven through 20 years of business success, contributing to Alturas’ reputation as a leader in the pharmaceutical industry.